<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02656095</url>
  </required_header>
  <id_info>
    <org_study_id>15-1412</org_study_id>
    <secondary_id>UL1TR001082</secondary_id>
    <nct_id>NCT02656095</nct_id>
  </id_info>
  <brief_title>Lipoprotein Lipase Enzyme Activity Assay Validation and Clinical Assessment</brief_title>
  <official_title>Lipoprotein Lipase Enzyme Activity Assay Validation and Clinical Assessment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Colorado, Denver</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Colorado, Denver</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study plans to learn more about measuring Lipoprotein lipase (LPL) activity in humans.&#xD;
      LPL is an enzyme in the breakdown of certain types of fats into smaller parts. Lipoprotein&#xD;
      lipase deficiency (LPLD) is a very rare genetic disorder in which lipoprotein enzyme is no&#xD;
      longer functional. This can cause conditions known as high triglycerides in the blood and&#xD;
      inflammation of the pancreas.&#xD;
&#xD;
      Investigational medications to treat LPLD are currently being developed. In order to see if&#xD;
      these medications are effective, it is necessary to be able to accurately measure LPL&#xD;
      activity in humans.&#xD;
&#xD;
      LPL activity has been successfully measured in animal models after giving heparin. Heparin is&#xD;
      a blood thinner which is approved by the FDA. It is originally used to prevent blood clots.&#xD;
      This study will administer heparin to healthy adults through intravenous infusion (IV). Blood&#xD;
      samples will be collected before and after the infusion to test LDL levels.&#xD;
&#xD;
      The purpose of this study is to develop a cheap, more reliable standard for assessment of&#xD;
      LPLD in patients&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 2016</start_date>
  <completion_date type="Actual">March 1, 2018</completion_date>
  <primary_completion_date type="Actual">March 1, 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluation of Lipoprotein lipase levels</measure>
    <time_frame>10-15 minutes post-heparin adminstration</time_frame>
    <description>Blood will be drawn after IV heparin administration and run through assay to determine lipoprotein lipase levels.</description>
  </primary_outcome>
  <enrollment type="Actual">12</enrollment>
  <condition>Lipoprotein Lipase Deficiency</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Heparin</intervention_name>
    <description>Participants will be given IV heparin in order to release lipoprotein lipase from capillary endothelial cells. Blood will be drawn 10-15 minutes post-heparin administration and run through assay to determine lipoprotein lipase levels.</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Healthy Male and female individuals&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        1. male and females between ages of 20-39&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Past history of LPL deficiency&#xD;
&#xD;
          2. Hypercholesterolemia (Cholesterol &gt;200, LDL &gt;160, HDL &lt;35) hypertriglyceridemia&#xD;
             (TG&gt;150), any familial lipid disorder&#xD;
&#xD;
          3. Diabetes mellitus (type 1 or 2)&#xD;
&#xD;
          4. Uncontrolled hypertension SBP&gt;140, DBP&gt;90&#xD;
&#xD;
          5. History of hemorrhagic stroke&#xD;
&#xD;
          6. Current pregnancy&#xD;
&#xD;
          7. History of major surgery, invasive procedure or trauma within the last 30 days, or&#xD;
             planned major surgery within 30 days after participating in the study&#xD;
&#xD;
          8. Exposure to heparin (unfractionated heparin or low molecular weight heparin) within 30&#xD;
             days prior to screening&#xD;
&#xD;
          9. History of allergy to heparin&#xD;
&#xD;
         10. History of heparin-induced thrombocytopenia&#xD;
&#xD;
         11. Current smoking&#xD;
&#xD;
         12. Active ulcerative or angiodysplastic GI diseases&#xD;
&#xD;
         13. Thrombocytopenia or platelet disorders (Platelet count &lt;100,000/UL)&#xD;
&#xD;
         14. Major health issues which may affect the safety of study subject, including but not&#xD;
             limited to:&#xD;
&#xD;
               -  History of chronic kidney disease (eGFR&lt;60)&#xD;
&#xD;
               -  Long term use of medications which alter lipid metabolism&#xD;
&#xD;
               -  History of hepatic disease (ALT or AST more than 2 times the upper limit of&#xD;
                  normal)&#xD;
&#xD;
               -  History of clotting disorders, any type of coagulation factor deficiency, or&#xD;
                  thrombocytopenia&#xD;
&#xD;
               -  Chronic use of ASA, anticoagulants, platelet inhibitors&#xD;
&#xD;
               -  Use of NSAIDS for more than 2 weeks prior to screening&#xD;
&#xD;
               -  Anemia (hemoglobin &lt;13 g/dL)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>39 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert Eckel, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Colorado, Denver</affiliation>
  </overall_official>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>January 12, 2016</study_first_submitted>
  <study_first_submitted_qc>January 13, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 14, 2016</study_first_posted>
  <last_update_submitted>July 9, 2019</last_update_submitted>
  <last_update_submitted_qc>July 9, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 11, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperlipoproteinemia Type I</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heparin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

